Processa Pharmaceuticals, Inc. Cash Flow Statement
PCSA|6 years of annual SEC 10-K data (FY2013-FY2022)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Processa Pharmaceuticals, Inc. used $9M in operating cash flow in FY2022.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|
| Net Income | -$11.4M | -$14.4M | -$3.4M | -$4.5M | -$3.1M | -$2.4M |
| Depreciation & Amortization | $484 | $8.4K | $60.3K | $71.0K | $57.8K | $19.2K |
| Operating Cash Flow | -$8.7M | -$3.1M | -$871.9K | -$2.7M | -$2.5M | -$1.9M |
| Capital Expenditures | - | - | $1.4K | $11.0K | $27.7K | $334.3K |
| Free Cash Flow | - | - | -$873.3K | -$2.7M | -$2.6M | -$2.2M |
| Share Buybacks | $300.0K | - | - | - | - | - |
| Dividends Paid | - | - | - | $45.6K | - | - |
| FCF Margin | - | - | -769.9% | -2520.2% | -821.3% | -1158.9% |